News

Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.

Scientists at UdeM's Department of Biochemistry and Molecular Medicine design better molecules that make it harder for plasmids to move between bacteria.

A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.

“We are very pleased to see that it looks like the vaccine has the potential to cover most of the strains of meningococcal Group B bacteria currently circulating in the U.S.,” said lead study author Gowrisankar Rajam, Ph.D.

Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.

Identification of three molecules that can be used to accurately assess pre-diabetes – a key predictor of conditions such as diabetes and high blood pressure – has brought precision medicine for humans a step closer.

The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.

In a significant step toward personalized medicine for cystic fibrosis, a minimally-invasive technique shows promise as a fast, inexpensive indicator to help more patients access new treatments.

A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.

When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.